Cidara Therapeutics Inc (CDTX.OQ)
CDTX.OQ on NASDAQ Stock Exchange Global Market
5.20USD
23 May 2018
5.20USD
23 May 2018
Change (% chg)
$0.30 (+6.12%)
$0.30 (+6.12%)
Prev Close
$4.90
$4.90
Open
$5.00
$5.00
Day's High
$5.40
$5.40
Day's Low
$4.95
$4.95
Volume
76,394
76,394
Avg. Vol
39,070
39,070
52-wk High
$8.80
$8.80
52-wk Low
$3.72
$3.72
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Buy | -0.70 | December | 25 May 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 4 | 4 | 4 | 5 |
| (2) OUTPERFORM | 4 | 3 | 3 | 3 |
| (3) HOLD | 0 | 0 | 0 | 1 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.50 | 1.43 | 1.43 | 1.56 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 6 | 0.00 | 0.00 | 0.00 | 0.39 |
| Quarter Ending Sep-18 | 6 | 0.00 | 0.00 | 0.00 | 0.39 |
| Year Ending Dec-18 | 7 | 0.00 | 0.00 | 0.00 | 1.18 |
| Year Ending Dec-19 | 7 | 0.00 | 0.00 | 0.00 | 0.30 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 6 | -0.70 | -0.55 | -0.83 | -0.73 |
| Quarter Ending Sep-18 | 6 | -0.73 | -0.56 | -0.87 | -0.75 |
| Year Ending Dec-18 | 7 | -3.01 | -2.49 | -3.29 | -3.33 |
| Year Ending Dec-19 | 6 | -2.99 | -1.94 | -3.98 | -2.88 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 0.26 | 0.00 | 0.26 | 100.00 |
| Quarter Ending Dec-17 | 0.26 | 0.00 | 0.26 | 100.00 |
| Quarter Ending Sep-17 | 0.21 | 0.00 | 0.21 | 100.00 |
| Quarter Ending Jun-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | -0.64 | -0.80 | 0.16 | -24.22 |
| Quarter Ending Dec-17 | -0.76 | -0.69 | 0.07 | -9.37 |
| Quarter Ending Sep-17 | -0.94 | -0.73 | 0.21 | -22.52 |
| Quarter Ending Jun-17 | -0.88 | -0.99 | 0.11 | -12.32 |
| Quarter Ending Mar-17 | -0.88 | -0.80 | 0.08 | -9.09 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 0.00 | 0.00 | 0.26 | 0.26 | 0.39 |
| Quarter Ending Sep-18 | 0.00 | 0.00 | 0.25 | 0.25 | 0.39 |
| Year Ending Dec-18 | 0.00 | 0.00 | 0.61 | 0.61 | 1.18 |
| Year Ending Dec-19 | 0.00 | 0.00 | 1.10 | 1.10 | 0.30 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -0.70 | -0.73 | -0.64 | -0.64 | -0.73 |
| Quarter Ending Sep-18 | -0.73 | -0.72 | -0.67 | -0.67 | -0.75 |
| Year Ending Dec-18 | -3.01 | -2.98 | -2.88 | -2.88 | -3.33 |
| Year Ending Dec-19 | -2.99 | -2.97 | -2.50 | -2.50 | -2.88 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 0 | 0 | 0 | 2 |
| Earnings | ||||
| Quarter Ending Jun-18 | 1 | 0 | 2 | 3 |
| Quarter Ending Sep-18 | 0 | 1 | 1 | 4 |
| Year Ending Dec-18 | 1 | 0 | 2 | 4 |
| Year Ending Dec-19 | 1 | 0 | 1 | 3 |
Earnings vs. 
Estimates- BRIEF-Cidara Announces Stock And Warrants Offering Worth $120 Mln
- BRIEF-Cidara Therapeutics Files For Stock Shelf Of Up To $10 Mln
- BRIEF-Cidara Reports Q1 Loss Per Share $0.80
- BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin
- BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin